ALZAMEND NEURO INC
ALZNNASDAQTrading Snapshot
- Day Range
- $1.79 – $1.86
- 52-Week Range
- $0.84 – $2.68
- Volume
- $2.65B
- Avg Volume
- $2.93B
- Shares Outstanding
- 3.8M
- Next Earnings
- Nov 8, 2026
Fundamentals Snapshot
- Annual Revenue
- $824,360
- Last Q Revenue
- $214,523
- P/E Ratio
- -0.8
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-2.03
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +32.5%
Why Investors Own ALZN
- ✓High-growth profile — revenue up +37.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 61% gross margin and 13% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ALZAMEND NEURO INC
ALZN
StockOtter · stockotter.spaceAbout ALZAMEND NEURO INC
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC
Neuroscience 2026, the annual meeting of the Society for Neuroscience, will be held November 14–18, 2026 in Washington, DC Presentation Title: Assessing Treatment-Associated Brain Network Changes Following a Novel Lith
Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain
ISMRM Workshop on Beyond Protons: Challenges and Advances in X-Nuclei MR will be held September 28 – October 1, 2026 at the Universitat Oberta de Catalunya (UOC) in Barcelona, Spain Presentation will report first-of-it
Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending
Company received $7.5 million in gross proceeds from the initial tranche of Series D Convertible Preferred Stock Agreement provides for up to $17.5 million in additional funding through subsequent tranche closings to sup